Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2002 1
2014 1
2015 7
2016 27
2017 18
2018 22
2019 18
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

86 results
Results by year
Filters applied: . Clear all The asterisk in your search was ignored. You must use 4 or more characters for a wildcard search. Lengthen the root word to search for all endings. The following term was ignored: ( Quoted phrase not found: "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6,11,16,18"
Page 1
Secondary prevention of cervical cancer.
Basu P, Mittal S, Bhadra Vale D, Chami Kharaji Y. Basu P, et al. Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:73-85. doi: 10.1016/j.bpobgyn.2017.08.012. Epub 2017 Sep 6. Best Pract Res Clin Obstet Gynaecol. 2018. PMID: 28988647 Review.
Treatment is safe and effective with ablative or excisional techniques. The World Health Organization recommends screening women at least once in a lifetime between 30 and 49 years of age and ensuring effective treatment of the detected abnormalities. …
Treatment is safe and effective with ablative or excisional techniques. The World Health Organization recommends screening wom …
Human papillomavirus and cervical cancer.
Okunade KS. Okunade KS. J Obstet Gynaecol. 2019 Dec 11:1-7. doi: 10.1080/01443615.2019.1674261. Online ahead of print. J Obstet Gynaecol. 2019. PMID: 31825273
Cervical cancer is by far the most common HPV-related disease. About 99.7% of cervical cancer cases are caused by persistent genital high-risk human papillomavirus (HPV) infection. ...There are currently two effective prophylactic vaccines again …
Cervical cancer is by far the most common HPV-related disease. About 99.7% of cervical cancer cases are caused by persistent genital …
Human papillomavirus and cervical cancer.
Okunade KS. Okunade KS. J Obstet Gynaecol. 2019 Sep 10:1-7. doi: 10.1080/01443615.2019.1634030. Online ahead of print. J Obstet Gynaecol. 2019. PMID: 31500479
Cervical cancer is by far the most common HPV-related disease. About 99.7% of cervical cancer cases are caused by persistent genital high-risk human papillomavirus (HPV) infection. ...There are currently two effective prophylactic vaccines again …
Cervical cancer is by far the most common HPV-related disease. About 99.7% of cervical cancer cases are caused by persistent genital …
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A. Huh WK, et al. Lancet. 2017 Nov 11;390(10108):2143-2159. doi: 10.1016/S0140-6736(17)31821-4. Epub 2017 Sep 5. Lancet. 2017. PMID: 28886907 Clinical Trial.
BACKGROUND: Primary analyses of a study in young women aged 16-26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease related to HPV 31, 33, 45, 52, and …
BACKGROUND: Primary analyses of a study in young women aged 16-26 years showed efficacy of the nine-valent human papillomavirus (9vHP …
Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials.
Safaeian M, Castellsagué X, Hildesheim A, Wacholder S, Schiffman MH, Bozonnat MC, Baril L, Rosillon D; Costa Rica HPV Vaccine Trial and the PATRICIA study groups. Safaeian M, et al. J Infect Dis. 2018 Jun 5;218(1):84-94. doi: 10.1093/infdis/jiy112. J Infect Dis. 2018. PMID: 29718393 Free PMC article. Clinical Trial.
BACKGROUND: Studies on the role of antibodies produced after infection with human papillomavirus 18 (HPV-18) and subsequent protection from HPV-18 infection have been conflicting, mainly due to inadequate sample size. METHODS: We pooled data from the control …
BACKGROUND: Studies on the role of antibodies produced after infection with human papillomavirus 18 (HPV-18) and subsequent pr …
Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil.
Inbar R, Weiss R, Tomljenovic L, Arango MT, Deri Y, Shaw CA, Chapman J, Blank M, Shoenfeld Y. Inbar R, et al. Immunol Res. 2017 Feb;65(1):136-149. doi: 10.1007/s12026-016-8826-6. Immunol Res. 2017. PMID: 27421722
We sought to evaluate the effects of Al adjuvant and the HPV vaccine Gardasil versus the true placebo on behavioral and inflammatory parameters in female mice. ...Immunohistochemistry analysis revealed microglial activation in the CA1 area of the hippo …
We sought to evaluate the effects of Al adjuvant and the HPV vaccine Gardasil versus the true placebo on behavioral
Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.
Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, Saah AJ, Drury R, Das R, Velicer C. Garland SM, et al. Clin Infect Dis. 2016 Aug 15;63(4):519-27. doi: 10.1093/cid/ciw354. Epub 2016 May 26. Clin Infect Dis. 2016. PMID: 27230391 Free PMC article. Review.
Prophylactic human papillomavirus (HPV) vaccination programs constitute major public health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) vaccination on HPV infection and disease. ...The fu …
Prophylactic human papillomavirus (HPV) vaccination programs constitute major public health initiatives w …
Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies.
Rosillon D, Baril L, Del Rosario-Raymundo MR, Wheeler CM, Skinner SR, Garland SM, Salmeron J, Lazcano-Ponce E, Vallejos CS, Stoney T, Ter Harmsel B, Lim TYK, Quek SC, Minkina G, McNeil SA, Bouchard C, Fong KL, Money D, Ilancheran A, Savicheva A, Cruickshank M, Chatterjee A, Fiander A, Martens M, Bozonnat MC, Struyf F, Dubin G, Castellsagué X. Rosillon D, et al. Cancer Med. 2019 Aug;8(10):4938-4953. doi: 10.1002/cam4.1879. Epub 2019 Jul 5. Cancer Med. 2019. PMID: 31273942 Free PMC article.
BACKGROUND: Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti-HPV antibodies is uncertain. We examined the risk of HPV infections as define …
BACKGROUND: Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the d …
Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy.
Lipkind HS, Vazquez-Benitez G, Nordin JD, Romitti PA, Naleway AL, Klein NP, Hechter RC, Jackson ML, Hambidge SJ, Lee GM, Sukumaran L, Kharbanda EO. Lipkind HS, et al. Obstet Gynecol. 2017 Sep;130(3):599-608. doi: 10.1097/AOG.0000000000002191. Obstet Gynecol. 2017. PMID: 28796684 Free PMC article. Clinical Trial.
METHODS: We conducted a retrospective, observational cohort study using administrative and health care data from the Vaccine Safety Datalink. ...CONCLUSION: Quadrivalent HPV vaccine inadvertently administered in pregnancy or during the periconce …
METHODS: We conducted a retrospective, observational cohort study using administrative and health care data from the Vaccin
Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women.
Sakamoto M, Miyagi E, Sumi Y, Aisaka K, Kuno N, Nagano H, Asahara S, Han SR, Wakana A, Murata S, Sawata M, Tanaka Y. Sakamoto M, et al. J Infect Chemother. 2019 Jul;25(7):520-525. doi: 10.1016/j.jiac.2019.02.012. Epub 2019 Mar 15. J Infect Chemother. 2019. PMID: 30879979 Free article. Clinical Trial.
This study for the first time assessed quadrivalent human papillomavirus (qHPV) vaccine effectiveness against HPV6/11/16/18-related high-grade cervical disease in Japanese women (16-26 years old), as previously demonstrated in overseas trials, and vaccine
This study for the first time assessed quadrivalent human papillomavirus (qHPV) vaccine effectiveness against HPV6/11/1 …
86 results
Jump to page
Feedback